BioLargo, Inc.
BLGO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $18 | $12 | $6 | $3 |
| % Growth | 45.4% | 107.9% | 132.5% | – |
| Cost of Goods Sold | $10 | $6 | $3 | $1 |
| Gross Profit | $8 | $6 | $3 | $1 |
| % Margin | 44.2% | 50.3% | 48.6% | 43.6% |
| R&D Expenses | $3 | $2 | $1 | $1 |
| G&A Expenses | $9 | $0 | $0 | $0 |
| SG&A Expenses | $9 | $8 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $12 | $10 | $8 | $7 |
| Operating Income | -$4 | -$4 | -$5 | -$6 |
| % Margin | -24.4% | -34.2% | -87% | -252.1% |
| Other Income/Exp. Net | $2 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$2 | -$5 | -$5 | -$7 |
| Tax Expense | $2 | $0 | $0 | $0 |
| Net Income | -$2 | -$4 | -$4 | -$7 |
| % Margin | -13.5% | -28.7% | -76.4% | -291.5% |
| EPS | -0.008 | -0.012 | -0.017 | -0.03 |
| % Growth | 34.1% | 26.8% | 43.6% | – |
| EPS Diluted | -0.008 | -0.012 | -0.017 | -0.03 |
| Weighted Avg Shares Out | 298 | 286 | 268 | 247 |
| Weighted Avg Shares Out Dil | 298 | 286 | 268 | 247 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$4 | -$5 | -$7 |
| % Margin | -22.8% | -34.2% | -86.6% | -264.8% |